Evidence map›Paper›PMID 24177258›Full record

ReviewLeukemia2014

International Myeloma Working Group recommendations for global myeloma care.

H Ludwig, J S Miguel, M A Dimopoulos, A Palumbo, R Garcia Sanz, R Powles, S Lentzsch, W Ming Chen, J Hou, A Jurczyszyn and 11 more

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05199311 (A Phase I/II Study of Carfilzomib, Iberdomide), which is not on this map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05199311 phase1 / phase2suspendednot on this mapstarted 2022, after this paper: background citation

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

TypeinterventionalSponsorHackensack Meridian HealthRan2022 to 2027Enrolled66ConditionsMultiple MyelomaArmsCarfilzomib, Iberdomide, Oral Dexamethasone
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

H LudwigDepartment of Medicine I, Center of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
J S MiguelClinica Universidad de Navarra, Pamplona, Spain.
M A DimopoulosDepartment of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece.
A PalumboMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
R Garcia SanzServicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain.
R PowlesParkside Cancer Centre, London, UK.
S LentzschColumbia University Medical Center, New York, NY, USA.
W Ming ChenChaoyang Hospital, Capital Medical University, Beijing, China.
J HouShanghai Chang Zheng Hospital, Shanghai, China.
A JurczyszynDepartment of Hematology, University Hospital, Cracow, Poland.
K RomerilHaematology Department, Wellington Hospital, Wellington, New Zealand.
R HajekDepartment of Internal Medicine, University of Ostrava, Ostrava, Czech Republic.
E TerposDepartment of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece.
K ShimizuNagoya City Midori General Hospital, Nagoya, Japan.
D JoshuaInstitute of Hematology, Royal Prince Alfred Hospital, Sydney, Australia.
V HungriaSanta Casa de Sao Paulo, Sao Paolo, Brazil.
A Rodriguez MoralesBonco Metro Politano de Sangre, Caracas, Venezuela.
D Ben-YehudaDepartment of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
P SondergeldUniversity of Giessen, Giessen, Germany.
E ZamagniIstituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy.
B DurieCedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

Indexed as

HumansMonitoring, PhysiologicMultiple MyelomaRecurrenceTreatment Outcome

Identifiers

PMID24177258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.